Palisade Bio
PALI
5 hedge funds and large institutions have $1.26M invested in Palisade Bio in 2018 Q2 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 5 → 5 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
35% less capital invested
Capital invested by funds: $1.94M → $1.26M (-$683K)
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$31K |
PALI Hedge Fund Activity: Q2 2018 in Review
5 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Palisade Bio (PALI) for Q2 2018, worth a combined $1.26M — down 35% from $1.94M a quarter earlier.
Fund positioning in PALI was balanced in Q2 2018: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.
The largest seller was Citadel Advisors, cutting an estimated $31K.
- 5 institutional investors held Palisade Bio (PALI) as of Q2 2018, unchanged from Q1 2018.
- Funds reported $1.26M of Palisade Bio stock for Q2 2018, down 35% quarter-over-quarter.
- 0 funds opened new Palisade Bio positions in Q2 2018 and 0 closed out.
- The largest Palisade Bio seller in Q2 2018 was Citadel Advisors, an estimated $31K sold.
Based on aggregated 13F filings for Q2 2018.